

EndoPredict® outperforms Oncotype DX® in accurately identifying low risk and high risk patients

In the TransATAC study, **928 patients** treated only with endocrine therapy were evaluated with EndoPredict and Oncotype DX.

EndoPredict exceeds Oncotype DX in accurately identifying **low risk** patients in all groups.^{1,2}

Distant metastases in the **low risk groups** after 10 years



5,8%

All patients



10,1%

Oncotype DX (RS)

EndoPredict (EPclin)



5%

Node positive



25,1%

Oncotype DX (RS)

EndoPredict (EPclin)



5,9%

Node negative




5,3%

Oncotype DX (RS)

EndoPredict (EPclin)

EndoPredict outperforms Oncotype DX in accurately identifying **high risk** patients and provides the most reliable information for chemotherapy decisions.



Conclusions:

- EPclin is highly prognostic for distant recurrence in all patients, in node negative patients, and especially in node positive patients.
- EPclin is highly prognostic for early metastasis (0-5 years) and late metastasis (5-10 years).
- EPclin provided more accurate prognostic information than the Recurrence Score.

EndoPredict gives more certainty than Oncotype DX in low risk and high risk groups, reliably identifying women who may be safely treated with endocrine therapy alone.

EndoPredict®
FOR PERSONALIZED BREAST CANCER TREATMENT

1. Dowsett M *et al*; EndoPredict (EPclin) score for estimating residual distant recurrence (DR) risk in ER+/HER2- breast cancer (br ca) patients treated with 5 years adjuvant endocrine therapy alone: Validation and comparison with the oncotype DX recurrence score (RS). SABCS; [S3-01]; 2015
2. <http://breastcancer.org/news-and-blogs/news/new-test-could-improve-prediction-of-breast-cancer-spread>



Produced by:
Sividon Diagnostics GmbH
Nattermannallee 1
50829 Köln, Germany
www.endopredict.com



Distributed by:
Myriad Genetics GmbH
Leutschenbachstrasse 95
8050 Zurich, Switzerland
www.myriadgenetics.eu